NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NYXH

Nyxoah SA

Jul 01 • 04:00PM ET

7.55

Dollar change +0.07
Percentage change 0.94	%

Healthcare • Medical Instruments & Supplies • Belgium • NASD

Peers: INSP PODD TNDM IART NVRO ZBH GMED SENS SGHT BFLY

| Held by: DFIC BMED DFIS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.13	Insider Own	54.39%	Shs Outstand	37.43M	Perf Week	-2.71%
Market Cap	282.60M	Forward P/E	-	EPS next Y	-2.09	Insider Trans	0.00%	Shs Float	17.07M	Perf Month	-1.31%
Enterprise Value	238.36M	PEG	-	EPS next Q	-0.63	Inst Own	20.85%	Short Float	0.69%	Perf Quarter	8.17%
Income	-74.72M	P/S	60.26	EPS this Y	-23.74%	Inst Trans	-4.13%	Short Ratio	0.75	Perf Half Y	-5.62%
Sales	4.69M	P/B	2.82	EPS next Y	14.15%	ROA	-55.58%	Short Interest	0.12M	Perf YTD	-5.62%
Book/sh	2.68	P/C	4.15	EPS next 5Y	10.67%	ROE	-76.77%	52W High	11.87 -36.39%	Perf Year	9.90%
Cash/sh	1.82	P/FCF	-	EPS past 3/5Y	-12.56% -34.68%	ROIC	-60.85%	52W Low	5.55 36.04%	Perf 3Y	-46.42%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	69.34% -	Gross Margin	-0.44%	Volatility	3.94% 4.00%	Perf 5Y	-
Dividend TTM	-	EV/Sales	50.82	EPS Y/Y TTM	-30.18%	Oper. Margin	-1557.24%	ATR (14)	0.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.35	Sales Y/Y TTM	-15.58%	Profit Margin	-1593.89%	RSI (14)	50.16	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	3.59	EPS Q/Q	-39.68%	SMA20	-1.82%	Beta	1.67	Target Price	13.59
Payout	-	Debt/Eq	0.24	Sales Q/Q	-15.50%	SMA50	6.88%	Rel Volume	0.17	Prev Close	7.48
Employees	-	LT Debt/Eq	0.22	Earnings	May 14 BMO	SMA200	-11.96%	Avg Volume	156.10K	Price	7.55
IPO	Apr 28, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-28.20% -36.42%	Trades		Volume	25,983	Change	0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-31-23	Initiated	H.C. Wainwright	Buy
Jul-19-23	Initiated	Robert W. Baird	Neutral
Apr-21-22	Initiated	Oppenheimer	Outperform	$30
Apr-06-22	Initiated	Wolfe Research	Peer Perform	$21
Dec-21-21	Resumed	Cantor Fitzgerald	Overweight	$47
Jul-28-21	Initiated	Cantor Fitzgerald	Overweight	$43

Jun-27-25 04:30PM	Information on the total number of voting rights and shares (GlobeNewswire)
Jun-13-25 01:00AM	Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 2, 2025 (GlobeNewswire)
May-30-25 04:30PM	Publication relating to transparency notifications (GlobeNewswire)
May-28-25 04:30PM	Nyxoah to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-25 04:30PM	Information on the total number of voting rights and shares (GlobeNewswire) -6.97%
07:35AM	Loading…
May-14-25 07:35AM	Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
01:00AM	Nyxoah Reports First Quarter Financial and Operating Results (GlobeNewswire)
May-09-25 04:30PM	Publication relating to transparency notifications (GlobeNewswire) -5.08%
01:00AM	Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 11, 2025 (GlobeNewswire)
May-08-25 07:15AM	Claritev Corporation (CTEV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-07-25 05:15PM	Health Catalyst (HCAT) Q1 Earnings Meet Estimates (Zacks)
04:30PM	Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 (GlobeNewswire)
May-06-25 05:55PM	Clover Health Investments, Corp. (CLOV) Surpasses Q1 Earnings Estimates (Zacks)
Apr-16-25 02:00AM	Conditional Issuance of Shares (GlobeNewswire)
Apr-08-25 01:00AM	Nyxoah Provides Update on FDA Approvable Letter for Genio System (GlobeNewswire) +6.13%
03:00AM	Loading…
Mar-26-25 03:00AM	FDA Issues Nyxoah an Approvable Letter for its Genio System (GlobeNewswire) -21.36%
Mar-13-25 02:00AM	Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results (GlobeNewswire)
Mar-10-25 05:05PM	Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025 (GlobeNewswire)
Mar-03-25 04:30PM	Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference (GlobeNewswire)
Feb-19-25 01:05AM	Nyxoah Announces Commercial Launch of Genio Breakthrough Therapy in the Middle East (GlobeNewswire)
Jan-20-25 04:30PM	Publication relating to transparency notifications (GlobeNewswire)
Dec-20-24 04:30PM	Publication relating to transparency notifications (GlobeNewswire)
Dec-13-24 02:05AM	Nyxoah Announces Commercial Launch of Genio Innovative Therapy in England (GlobeNewswire)
Nov-27-24 04:30PM	Information on the total number of voting rights and shares (GlobeNewswire)
Nov-20-24 04:05PM	Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-19-24 01:00AM	Invitation to attend the special shareholders' meeting of the Company to be held on December 19, 2024 (GlobeNewswire)
Nov-18-24 04:30PM	Publication relating to transparency notifications (GlobeNewswire)
Nov-06-24 04:05PM	Nyxoah Reports Third Quarter Financial and Operating Results (GlobeNewswire)
Nov-04-24 04:45PM	Nyxoah Appoints John Landry as Chief Financial Officer (GlobeNewswire) +5.40%
Oct-25-24 04:30PM	Publication relating to transparency notifications (GlobeNewswire)
04:30PM	Loading…
Oct-22-24 04:30PM	Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-15-24 04:30PM	Publication relating to transparency notifications (GlobeNewswire)
Oct-09-24 04:35PM	Information on the total number of voting rights and shares (GlobeNewswire)
04:30PM	Publication relating to transparency notifications (GlobeNewswire)
Oct-08-24 05:49PM	Nyxoah Secures $27 Million to Boost U.S. Presence (TipRanks)
Oct-07-24 05:00PM	Nyxoah Raises $27 Million through its At-the-Market Offering (GlobeNewswire)
Sep-27-24 04:30PM	DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update (GlobeNewswire) +5.56%
02:05AM	Information on the total number of voting rights and shares (GlobeNewswire)
02:00AM	Publication relating to transparency notifications (GlobeNewswire)
Sep-05-24 04:30PM	Nyxoah to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 04:05PM	Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device (GlobeNewswire)
Aug-06-24 04:05PM	Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results (GlobeNewswire)
Jul-29-24 04:30PM	Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jul-15-24 02:00AM	Nyxoah Appoints Scott Holstine as Chief Commercial Officer (GlobeNewswire)
Jul-03-24 06:30AM	Nyxoah Has Signed a 37.5 Million Loan Facility Agreement with the European Investment Bank (GlobeNewswire) +5.27%
Jul-01-24 02:00AM	Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA (GlobeNewswire)
Jun-28-24 04:30PM	Information on the total number of voting rights and shares (GlobeNewswire)
Jun-03-24 04:30PM	Nyxoah to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -8.61%
04:15PM	Information on the total number of voting rights and shares (GlobeNewswire)
04:05PM	Publication relating to transparency notifications (GlobeNewswire)
May-31-24 02:00AM	Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares (GlobeNewswire)
May-28-24 04:30PM	Information on the Total Number of Voting Rights and Shares (GlobeNewswire)
May-23-24 09:59AM	Nyxoah Announces Pricing of Offering (GlobeNewswire) -17.69%
May-22-24 04:10PM	Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program (GlobeNewswire)
04:05PM	Nyxoah Announces Proposed Offering of Ordinary Shares (GlobeNewswire)
May-14-24 04:05PM	Nyxoah Reports First Quarter 2024 Financial and Operating Results (GlobeNewswire) +8.25% +7.20%
May-13-24 04:30PM	Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 (GlobeNewswire) +7.53%
May-10-24 01:00AM	Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 12, 2024 (GlobeNewswire)
Apr-30-24 01:31PM	ResMed Inc. (NYSE:RMD) Q3 2024 Earnings Call Transcript (Insider Monkey) -6.55%
Apr-11-24 04:30PM	Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer (GlobeNewswire) -10.41% -7.30%
Mar-29-24 04:30PM	Information on the total number of voting rights and shares (GlobeNewswire)
Mar-25-24 02:05AM	Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology Head & Neck Surgery Foundation (GlobeNewswire) -7.88%
Mar-19-24 04:05PM	Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints (GlobeNewswire) -14.21% -16.92%
Mar-07-24 09:45AM	Nyxoah S.A. (NASDAQ:NYXH) Q4 2023 Earnings Call Transcript (Insider Monkey) +8.22%
Mar-05-24 09:52PM	NYXH Stock Earnings: Nyxoah Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -5.24% -8.33%
04:05PM	Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results (GlobeNewswire)
Feb-29-24 04:30PM	Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference (GlobeNewswire) +7.07%
Feb-15-24 04:30PM	Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 (GlobeNewswire) +7.32%
Jan-17-24 04:05PM	Nyxoah Announces 2024 Strategic Priorities (GlobeNewswire) -6.04%
Jan-09-24 04:05PM	Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Dec-11-23 01:30AM	Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio (GlobeNewswire)
Dec-08-23 04:30PM	Publication Relating to a Transparency Notification (GlobeNewswire)
Nov-28-23 04:30PM	Nyxoah Strengthens its Executive Leadership Team (GlobeNewswire)
Nov-27-23 08:19AM	Why Is Nyxoah (NYXH) Stock Up 4% Today? (InvestorPlace)
Nov-21-23 04:30PM	Nyxoah to Participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-08-23 04:05PM	Nyxoah Reports Third Quarter 2023 Financial and Operating Results (GlobeNewswire) -15.10%
Nov-07-23 04:30PM	Nyxoah to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-26-23 04:30PM	Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Sep-28-23 04:30PM	Nyxoah Announces Partnership with ResMed in Germany (GlobeNewswire)
Sep-12-23 04:30PM	Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-05-23 04:30PM	Nyxoah to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-23 04:30PM	Information on the Total Number of Voting Rights and Shares (GlobeNewswire)
Aug-08-23 04:05PM	Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating Results (GlobeNewswire)
Jul-27-23 04:30PM	Publication Relating to a Transparency Notification (GlobeNewswire)
04:30PM	Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
04:30PM	Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference (GlobeNewswire)
04:30PM	Information on the Total Number of Voting Rights and Shares (GlobeNewswire)
May-16-23 04:05PM	Nyxoah Reports First Quarter 2023 Financial and Operating Results (GlobeNewswire)
May-12-23 01:00AM	Invitation to Attend the Annual Shareholders Meeting of the Company to be Held on June 14, 2023 (GlobeNewswire)
May-10-23 04:05PM	Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer (GlobeNewswire)
May-01-23 04:30PM	Nyxoah to Release First Quarter 2023 Financial Results on May 16, 2023 (GlobeNewswire) +7.79%
Apr-20-23 04:30PM	Publication Relating to Transparency Notifications (GlobeNewswire) +11.06%
Apr-17-23 04:30PM	Information on the Total Number of Voting Rights and Shares (GlobeNewswire) +10.01%
Apr-13-23 04:05PM	Nyxoah Raises $3 Million from its At-the-Market Equity Offering (GlobeNewswire) +10.19% +12.37%
Mar-31-23 04:30PM	Information on the Total Number of Voting Rights and Shares (GlobeNewswire)
Mar-27-23 04:05PM	Nyxoah Raises $3 Million from an At-the-Market Equity Offering (GlobeNewswire) +8.68%
Mar-23-23 04:05PM	Nyxoah Announces a $15 Million Private Placement Financing (GlobeNewswire)
Mar-22-23 04:05PM	Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating Results (GlobeNewswire)
Mar-08-23 04:30PM	Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023 (GlobeNewswire)
Mar-07-23 04:30PM	Nyxoah to Participate in the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NYXH

Nyxoah SA

Upgrade your FINVIZ experience